untitled.pdf (1.62 MB)
Validation of a commercially available indirect assay for SARS-CoV-2 neutralising antibodies using a pseudotyped virus assay
journal contribution
posted on 2023-06-10, 01:11 authored by Matthew J Murray, Megan McIntosh, Claire Atkinson, Tabitha Mahungu, Edward WrightEdward Wright, Wendy Chatterton, Michae Gandy, Matthew B ReevesObjectives To assess whether a commercially available CE-IVD, ELISA-based surrogate neutralisation assay (cPass, Genscript) provides a genuine measure of SARS-CoV-2 neutralisation by human sera, and further to establish whether measuring responses against the RBD of S was a diagnostically useful proxy for responses against the whole S protein. Methods Serum samples from 30 patients were assayed for anti-NP responses, for ‘neutralisation’ by the surrogate neutralisation assay and for neutralisation by SARS-CoV-2 S pseudotyped virus assays utilising two target cell lines. Correlation between assays was measured using linear regression. Results The responses observed within the surrogate neutralisation assay demonstrated an extremely strong, highly significant positive correlation with those observed in both pseudotyped virus assays. Conclusions The tested ELISA-based surrogate assay provides an immunologically useful measure of functional immune responses in a much quicker and highly automatable fashion. It also reinforces that detection of anti-RBD neutralising antibodies alone is a powerful measure of the capacity to neutralise viral infection.
History
Publication status
- Published
File Version
- Published version
Journal
Journal of InfectionISSN
0163-4453Publisher
ElsevierExternal DOI
Issue
5Volume
82Page range
170-177Event location
EnglandDepartment affiliated with
- Biochemistry Publications
Full text available
- Yes
Peer reviewed?
- Yes
Legacy Posted Date
2021-09-27First Open Access (FOA) Date
2021-09-27First Compliant Deposit (FCD) Date
2021-09-27Usage metrics
Categories
No categories selectedLicence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC